A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety of TEV-48125 for the Prevention of Cluster Headache

Trial Profile

A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety of TEV-48125 for the Prevention of Cluster Headache

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Fremanezumab (Primary)
  • Indications Cluster headache
  • Focus Adverse reactions
  • Acronyms ENFORCE
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 23 May 2017 Planned number of patients changed from 300 to 600.
    • 27 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top